慢性肢体威胁性缺血患者膝下动脉腔内再干预的结局与通畅率
这项回顾性多中心队列研究纳入2015年至2021年荷兰3家医院因慢性肢体威胁性缺血(CLTI)接受膝下动脉腔内再干预的患者,共81例患者、87条肢体、122处病变。技术成功率为81%(99处病变),30天死亡率为1%,并发症率为13%。1年总生存率和无截肢生存率(AFS)分别为69%和54%,2.5年分别为45%和21%。作者结论认为再干预的30天死亡率和并发症率可接受,但结局和通畅率中等至差。
要点
- 膝下动脉腔内再干预技术成功率为81%(99/122处病变)。
- 30天死亡率为1%,并发症率为13%。
- 1年AFS为54%,2.5年降至21%,再干预需求高。
核心结论
- 作者结论认为膝下动脉腔内再干预可在可接受的30天死亡率和并发症率下进行,但结局和通畅率中等至差,AFS低、大截肢率高且再干预率高。
研究设计与样本
- 回顾性多中心队列研究,纳入荷兰3家医院2015年至2021年因CLTI接受膝下动脉腔内再干预的患者81例、87条肢体、122处病变。
主要发现
- 技术成功率为81%(99处病变),30天死亡率为1%,并发症率为13%。
- 1年总生存率为69%(95%CI 55%-79%),AFS为54%(95%CI 37%-67%);2.5年总生存率为45%(95%CI 33%-56%),AFS为21%(95%CI 11%-33%)。
- 1年无大截肢率为59%(95%CI 46%-70%),无MALE率为54%(95%CI 41%-65%),无再干预率为68%(95%CI 55%-78%)。
- 2.5年无大截肢率为41%(95%CI 25%-56%),无MALE率为36%(95%CI 21%-51%),无再干预率为51%(95%CI 33%-66%)。
- GLASS评分III分与无大截肢或再干预生存期风险升高相关,HR为2.559(95%CI 1.078-6.072;p=0.033)。
临床怎么用
- 作者认为膝下动脉腔内再干预的30天死亡率和并发症率可接受,但短期至中期结局和通畅率中等至差。
- 作者提出可考虑静脉旁路移植或深静脉动脉化等替代治疗方案,并应在随机对照试验中研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Endovascular revascularization is the preferred treatment to improve perfusion of the lower extremity in patients with chronic limb-threatening ischemia (CLTI). Patients with CLTI often present with stenotic-occlusive lesions involving the infrapopliteal arteries. Although the frequency of treating infrapopliteal lesions is increasing, the reintervention rates remain high. This study aimed to determine the outcomes and patency of infrapopliteal endovascular reinterventions. METHODS: This retrospective, multicenter cohort study of 3 Dutch hospitals included patients who underwent an endovascular infrapopliteal reintervention in 2015 up to 2021 after a primary infrapopliteal intervention for CLTI. The outcome measures after the reintervention procedures included technical success rate, the mortality rate and complication rate (any deviation from the normal postinterventional course) at 30 days, overall survival, amputation-free survival (AFS), freedom from major amputation, major adverse limb event (MALE), and recurrent reinterventions (a reintervention following the infrapopliteal reintervention). Cox proportional hazard models were used to determine risk factors for AFS and freedom from major amputation or recurrent reintervention. RESULTS: Eighty-one patients with CLTI were included. A total of 87 limbs underwent an infrapopliteal reintervention in which 122 lesions were treated. Technical success was achieved in 99 lesions (81%). The 30-day mortality rate was 1%, and the complication rate was 13%. Overall survival and AFS at 1 year were 69% (95% confidence interval [CI], 55%-79%) and 54% (95% CI, 37%-67%), respectively, and those at 2.5 years were 45% (95% CI, 33%-56%) and 21% (95% CI, 11%-33%), respectively. Freedom from major amputation, MALE, and recurrent reinterventions at 1 year and 2.5 years were 59% (95% CI, 46%-70%) and 41% (95% CI, 25%-56%); 54% (95% CI, 41%-65%) and 36% (95% CI, 21%-51%); and 68% (95% CI, 55%-78%) and 51% (95% CI, 33%-66%), respectively. A Global Limb Anatomic Staging System score of III showed an increased hazard ratio of 2.559 (95% CI, 1.078-6.072; p=0.033) for freedom of major amputation or recurrent reintervention. CONCLUSIONS: The results of this study indicate that endovascular infrapopliteal reinterventions can be performed with acceptable 30-day mortality and complication rates. However, outcomes and patency were moderate to poor, with low AFS, high rates of major amputations, and recurrent reinterventions. CLINICAL IMPACT: This multicenter retrospective study evaluating outcome and patency of endovascular infrapopliteal reinterventions for CLTI, shows that endovascular infrapopliteal reinterventions can be performed with acceptable 30-day mortality and complication rates. However, the short- and mid-term outcomes of the infrapopliteal reinterventions were moderate to poor, with low rates of AFS and a high need for recurrent reinterventions. While the frequency of performing infrapopliteal reinterventions is increasing with additional growing complexity of the disease, alternative treatment options such as venous bypass grafting or deep venous arterialization may be considered and should be studied in randomized controlled trials.
引用
- Kleiss SF, van Mierlo-van den Broek PAH, Vos CG, et al. Outcomes and Patency of Endovascular Infrapopliteal Reinterventions in Patients With Chronic Limb-Threatening Ischemia. J Endovasc Ther. 2023. PMID: 36609175. doi:10.1177/15266028221147457
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。